Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis

Höer, Ariane; Seidlitz, Cornelia; Gothe, Holger; Schiffhorst, G.; Olson, Mark W.; Hadji, Peyman; Häussler, Bertram

doi:10.2147/ppa.s4673

Cited by 16 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a result, 70% of patients discontinue treatment during the first year [ 28 , 29 ]. Moreover, interruption of treatment will affect the efficacy of the drug, and the incidence of fractures is significantly higher than that of patients who insist on taking the drug [ 30 ]. Therefore, oral bisphosphonate treatment requires attention to patient compliance.…”

Section: Bone Health Management For Early Breast Cancer Patientsmentioning

confidence: 99%

Clinical practice guidelines for full‐cycle standardized management of bone health in breast cancer patients

2024

Cancer Innovation

View full text Add to dashboard Cite

Bone health management for breast cancer spans the entire cycle of patient care, including the prevention and treatment of bone loss caused by early breast cancer treatment, the adjuvant application of bone‐modifying agents to improve prognosis, and the diagnosis and treatment of advanced bone metastases. Making good bone health management means formulating appropriate treatment strategies and dealing with adverse drug reactions, and will help to improve patients' quality of life and survival rates. The Breast Cancer Expert Committee of the National Cancer Center for Quality Control organized relevant experts to conduct an in‐depth discussion on the full‐cycle management of breast cancer bone health based on evidence‐based medicine, and put forward reasonable suggestions to guide clinicians to better deal with health issues in bone health clinics.

show abstract

Section: Bone Health Management For Early Breast Cancer Patientsmentioning

confidence: 99%

Clinical practice guidelines for full‐cycle standardized management of bone health in breast cancer patients

2024

Cancer Innovation

View full text Add to dashboard Cite

show abstract

Adherence with intravenous zoledronate and intravenous ibandronate in the United States medicare population

Curtis¹,

Yun²,

Matthews³

et al. 2012

Arthritis Care & Research

View full text Add to dashboard Cite

Objective Our objective was to evaluate adherence among new users of zoledronate and IV ibandronate among U.S. Medicare enrollees. Methods We used data from the Medicare 5% random sample to evaluate new users of IV zoledronate and IV ibandronate with continuous Part A+B fee-for-service coverage. The outcome was adherence as quantified by the proportion of days covered (PDC), measured continuously and dichotomously (>= 80%). Follow-up time extended from 18–27 months for all individuals. Factors associated with low adherence with zoledronate were evaluated with logistic regression. Results We identified 775 new users of zoledronate and 846 new users of IV ibandronate. For both drugs, 30–48% of first infusions were given in an outpatient infusion center, not in a physician office. The mean PDC for zoledronate users was 82%, which was greater than the mean PDC for the IV Ibandronate users (58–62%, depending on time period, p < 0.0001). Approximately 30% of zoledronate users did not receive a second infusion. Factors associated with low adherence to zolendronate included older age and receipt of the first infusion in an outpatient infusion center rather than a physician’s office. Conclusions Less frequently dosed IV bisphosphonates have not resolved the problem of suboptimal adherence with prescription osteoporosis medications. Interventions continue to be warranted to improve long term adherence with osteoporosis treatments.

show abstract

Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study

et al. 2015

View full text Add to dashboard Cite

SummaryPersistence with and adherence to osteoporosis therapy are critical for fracture reduction. This non-interventional study is evaluating medication-taking behavior of women with postmenopausal osteoporosis (PMO) receiving denosumab in Germany, Austria, Greece, and Belgium. Patients were representative of the PMO population and highly persistent with and adherent to denosumab at 12 months.IntroductionPersistence with and adherence to osteoporosis therapy are important for optimal treatment efficacy, namely fracture reduction. This ongoing, non-interventional study will evaluate medication-taking behavior of women with postmenopausal osteoporosis (PMO) receiving denosumab in routine practice in four European countries.MethodsThe study enrolled women who had been prescribed subcutaneous denosumab (60 mg every 6 months) in accordance with prescribing information and local guidelines. Persistence was defined as receiving the subsequent injection within 6 months + 8 weeks of the previous injection. Adherence was defined as receiving two consecutive injections within 6 months ± 4 weeks of each other. Medication coverage ratio (MCR) was calculated using the time a patient was covered with denosumab, as assessed from prescription records. Treatment was assigned prior to and independently of enrollment; outcomes are recorded during routine practice.ResultsThese planned 12-month interim analyses included data from 1500 patients from 141 sites. Mean age was 66.4–72.4 years, mean baseline total hip T-scores ranged from −2.0 to −2.1 and femoral neck T-scores from −2.2 to −2.6, and 30.7–62.1 % of patients had prior osteoporotic fracture. Persistence was 87.0–95.3 %, adherence 82.7–89.3 %, and MCR 91.3–95.4 %. In a univariate analysis, increased age, decreased mobility, and increased distance to the clinic were associated with significantly decreased persistence; parental history of hip fracture was associated with significantly increased persistence.ConclusionsThese data extend the real-world evidence regarding persistence with and adherence to denosumab, both of which are critical for favorable clinical outcomes, including fracture risk reduction.Electronic supplementary materialThe online version of this article (doi:10.1007/s00198-015-3164-4) contains supplementary material, which is available to authorized users.

show abstract

Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis

Cited by 16 publications

References 9 publications

Clinical practice guidelines for full‐cycle standardized management of bone health in breast cancer patients

Clinical practice guidelines for full‐cycle standardized management of bone health in breast cancer patients

Adherence with intravenous zoledronate and intravenous ibandronate in the United States medicare population

Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study

Contact Info

Product

Resources

About